Biotech/Biopharma Investment for Family Offices, Funds or Focused Investors

searcher profile

April 08, 2025

by a searcher from University of Pennsylvania - The Wharton School in Los Angeles, CA, USA

I've been advising a Biotech/Biopharma company that has spent the last 5 years developing a groundbreaking and now patented drug delivery platform.

Two companies have sub-licensed the platform in the diabetes management and oncology spaces. Base on trials to date, both companies seem to have blockbuster potential,

Each is raising $7-$10M in Seed/Series A funding which will go to further testing on NHPs, building up the management team, starting fast-track FDA approval process and engaging a Big Pharma partner.

An early exit expected###-###-#### months). DM me for more details and to set up a chat.

0
7
52
Replies
7
commentor profile
Reply by a searcher
from University of Cambridge in London, UK
Likely not the right asset class for this type of investment. Drugs at this stage typically have less than a 5% chance of ultimate approval. Biotech and the standard search fund acquisition business model rarely overlap for this - and a dozen other - reasons. .
commentor profile
Reply by a searcher
from INSEAD in Liège, Belgium
In Belgium we have Noshaq and Wallonie Entreprendre that are very active in those kind of businesses. But as state-owned entities, their goal is to attract those companies in Belgium (where we have a strong biopharma ecosystem)
commentor profile
+5 more replies.
Join the discussion